var foresee_enabled = 1 } 'tb_loader_script'); Like all ChartIQ markers, the object itself is managed by the chart, so when you scroll the chart the object moves with you. var dynamic_yield_enabled = 1 for (var i in mps.response.dart.adunits) { script.setAttribute("src", "//www.npttech.com/advertising.js"); For more information, please fill out the form below and a representative from Capricor will be in touch with you shortly. if (mps.response && mps.response.dart && typeof(mps.response.dart.adunits) === 'object') { mps._debug('[MPS]: email address detected in url, bypass gpt. 'cag[template]' : 'quote_custom_redesign' , We have some new features we think you'll like. A Division of NBCUniversal. if(typeof document.getElementsByTagName('meta')['tp:PreferredRuntimes'] === 'object') { (adsbygoogle = window.adsbygoogle || []).push({}); BOVNews.com was originated in 2018 as a Company. 446,491 shares were traded during trading, a decline of 86% from the average session volume of 3,083,400 shares. } document.getElementsByTagName("head")[0].appendChild(script); mps.cloneAd = function() { return false; } // // mps.insertAd("#" + slotid, adunit) GAN Limited (GAN), Capricor Therapeutics... United Microelectronics Corporation (UMC) and Sealed Air Corporation (SEE) is Performing In A Tough... Strong Growth And Abundant Potential: Entasis Therapeutics Holdings Inc. (ETTX) and Seritage Growth Properties... Could generate strong returns? if (!document.getElementById(i)){ Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. script.setAttribute("async", true); })(); The drug, called CAP-1002, is Capricor’s lead candidate against Duchenne muscular dystrophy, a progressive disorder found primarily in children that causes muscles to become weaker over time. Get this delivered to your inbox, and more info about our products and services. document.cookie = "__adblocker=" + (adblocker ? var _regex = /([^=&/<>()[].,;:s@"]+(.[^=&/<>()[].,;:s@"]+)*)@(([[0-9]{1,3}.[0-9]{1,3}.[0-9]{1,3}.[0-9]{1,3}])|(([a-zA-Z-0-9]+. 'stitle' : 'detailed quote stub' , (r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1],r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],7:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=r.apply(this,arguments);return o.emit(n+"start",arguments,t),t.then(function(e){return o.emit(n+"end",[null,e],t),e},function(e){throw o.emit(n+"end",[e],t),e})})}var o=t("ee").get("fetch"),i=t(21);e.exports=o;var a=window,s="fetch-",c=s+"body-",f=["arrayBuffer","blob","json","text","formData"],u=a.Request,d=a.Response,p=a.fetch,l="prototype";u&&d&&p&&(i(f,function(t,e){r(u[l],e,c),r(d[l],e,c)}),r(a,"fetch",s),o.on(s+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(s+"done",[null,e],n)}else o.emit(s+"done",[t],n)}))},{}],8:[function(t,e,n){var r=t("ee").get("history"),o=t(24)(r);e.exports=r,o.inPlace(window.history,["pushState","replaceState"],"-")},{}],9:[function(t,e,n){function r(t){function e(){c.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}function n(){c.emit("jsonp-error",[],p),c.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var u=s(a),d="function"==typeof u.parent[u.key];if(d){var p={};f.inPlace(u.parent,[u.key],"cb-",p),t.addEventListener("load",e,!1),t.addEventListener("error",n,!1),c.emit("new-jsonp",[t.src],p)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(u);return e?e[1]:null}function a(t,e){var n=t.match(p),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(d);return e&&e.length>=3? var mpscall = { What can we imagine from Capricor Therapeutics Inc. (CAPR), Surgalign Holdings... Must be in your Portfolio: Capricor Therapeutics Inc. (CAPR), Raymond James... Capricor Therapeutics Inc. (CAPR) and Companhia Energetica de Minas Gerais (CIG)... Sally Beauty Holdings Inc. (SBH), Capricor Therapeutics Inc. (CAPR) Are Steady... Capricor Therapeutics Inc. (CAPR), Concho Resources Inc. (CXO) Are Steady Eddie... Old Ceiling Or A New Floor? var mps = mps || {}; To view our Corporate Deck please click here. “We look forward to continuing to treat additional patients under our recently approved expanded access program Investigational New Drug application. 'type' : 'quote' , The company has been preparing to enter CAP-1002 in late-stage clinical trials to treat DMD. e.id = i; mpsload.src = "//" + mpsopts.host + "/fetch/ext/load-" + mpscall.site + ".js?nowrite=2"; To view a complete list of our most recent and past events and presentations please click here. e.async = 1; (RTTNews) - Shares of Capricor Therapeutics, Inc. (CAPR) are currently surging nearly 80% on Wednesday morning after new data reports showed … 'https' : 'http') + '://pix.nbcuni.com/a-pii.gif?X=piiblock&S=' + mps.pagevars.instance + '&P=' + mps.pagevars.mpsid + '&A=' + i + '&U=' + encodeURIComponent(window.location.href) + '&_=' + window._mpspixZ; var script = document.createElement("script"); var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; But with the coronavirus pandemic, Capricor pivoted CAP-1002. {key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t("ee").get("jsonp"),f=t(24)(c);if(e.exports=c,o()){var u=/[?&](?:callback|cb)=([^&#]+)/,d=/(.*)\.([^.]+)/,p=/^(\w+)(\.|$)(. 'cag[symbol]' : 'CAPR' , 'id' : '101' , head.insertBefore(mpsload, head.firstChild) }); 'content_id' : '101' , "),a=0;a